未經授權許可禁止轉載！

2024年10月16日，百裕制藥與諾華就一款小分子抗腫瘤藥物簽訂獨家許可協議。

-根據協議，百裕將收到7000萬美元首付款，以及可達11億美元的開發、注冊及商業化等各類里程碑付款和相應特許使用費。

-諾華將獲得該款小分子創新藥的全球獨家開發及商業化權利。

-BFC Group在本次交易中擔任百裕制藥獨家財務顧問。

-這次戰略合作是百裕向全球患者提供潛在抗腫瘤藥物重要一步，期待積極成果實現。

百裕制藥總部位于中國成都，專注于藥物發明發現，多次榮獲國家獎項，專注銀杏核心藥效成分研究二十余年，成功開發現代植物藥（銀杏葉有效部位制劑）“銀杏內酯注射液”及“銀杏總內酯滴丸”。

Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor

CHENGDU, Oct.16^th, 2024 -- Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset.

Under the terms of the license agreement, Baiyu will receive an upfront payment of $70 million and is eligible to receive additional development, regulatory and commercial milestones payments of up to $1.1 billion, as well as tiered royalties.

Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset.

BFC Group acted as the exclusive financial advisor to Baiyu.

This collaboration is an important step for Baiyu in making potential anti-tumor drugs available to patients globally, and Baiyu look forward to positive results being realized.

About Chengdu Baiyu Biopharmaceutical Co., Ltd.

Founded in 2005, Baiyu is a pharmaceutical company headquartered in Chengdu, China. The company is dedicated to discover and develop innovative medicines, for which it has earned numerous prestigious national awards. With over 20 years of focused research on the core pharmacological components of Ginkgo biloba, we have successfully developed modern botanical drugs, including Ginkgolide Injection and Ginkgolide Dropping Pills.